Researchers find possible key to preventing chemotherapy resistance in ovarian cancer
For patients with ovarian cancer and their physicians, resistance to chemotherapy is a serious concern. However, researchers at Moffitt Cancer Center have identified a molecular pathway that may play a key role in the evolution of chemotherapy resistance. They are hopeful that the discovery may lead to therapies that are tailored to individual patients with ovarian cancer; reversing resistance to chemotherapy and improving survival from the disease.
"Few clinical or biologic events affect survival for patients with ovarian cancer more than the way their tumors respond to chemotherapy," said Johnathan Lancaster, M.D., Ph.D., senior author on a study into chemotherapy resistance recently published in the journal Clinical Cancer Research (17:00, 2011). "We identified a pathway called the 'BCL2 antagonist of cell death,' or BAD, and determined that the activity of the BAD pathway may have more influence on survival than the volume of residual disease after primary surgery."
According to Lancaster and colleagues, the discovery of BAD opens the door to using the pathway as a biomarker to identify patients with the highest-risk ovarian cancer, which are genetically programmed to be resistant to chemotherapy; enabling physicians to identify patients who might benefit from drugs that inhibit the BAD pathway such that chemo-resistance is reversed.
"Targeted therapies that increase a tumor's sensitivity to chemotherapy offer the potential to improve patient survival," explained Lancaster, chair of the Department of Women's Oncology and director of the Center for Women's Oncology at Moffitt.
By treating ovarian cancer cells in a test tube (in vitro) with a chemotherapy drug and observing which genetic pathways became most active, the researchers identified the BAD pathway. To further analyze the activity of the BAD pathway and levels of the BAD protein, the researchers examined tumor specimens and genomic information from almost 300 patients with advanced ovarian cancer. A 47-gene BAD pathway signature was developed and was found to be associated with survival. Subsequent in vitro tests on ovarian cancer cells suggest that it may be possible to inhibit the BAD pathway and reverse resistance to chemotherapy.
"Intriguingly, patients who had lots of cancer remaining at the conclusion of their surgery but whose tumors had low levels of pBAD protein, had better survival than patients with very little cancer remaining following surgery, but who had high levels of pBAD protein," said Lancaster. "Although our data highlights the importance of this newly identified pathway, not all cell line samples showed associations between chemotherapy resistance and BAD pathway genes. There are likely many other pathways and processes contributing to chemotherapy resistance."
The researchers concluded that although more research is necessary, BAD pathway-based biomarkers could open the door to personalized treatment for ovarian cancer by placing women in high-risk and low-risk groups based on their genetic profile for the BAD pathway and protein. Treatments could be selected for each patient according to the status of their BAD pathway.
Provided by H. Lee Moffitt Cancer Center & Research Institute
- Experimental drug inhibits cell signaling pathway and slows ovarian cancer growth Apr 15, 2011 | not rated yet | 0
- Loss of protein could contribute to early breast and ovarian cancer deaths Feb 01, 2011 | not rated yet | 0
- Expression of Proteins Linked to Poor Outcome in Women with Ovarian Cancer Apr 20, 2010 | not rated yet | 0
- Ovarian cancer advances when genes are silenced Dec 13, 2010 | not rated yet | 0
- Genetic approach provides new insight into trastuzumab resistance in breast cancer Oct 15, 2007 | not rated yet | 0
- Motion perception revisited: High Phi effect challenges established motion perception assumptions Apr 23, 2013 | 3 / 5 (2) | 2
- Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update) Apr 02, 2013 | 4.5 / 5 (11) | 5
- The visual system as economist: Neural resource allocation in visual adaptation Mar 30, 2013 | 5 / 5 (2) | 9
- Separate lives: Neuronal and organismal lifespans decoupled Mar 27, 2013 | 4.9 / 5 (8) | 0
- Sizing things up: The evolutionary neurobiology of scale invariance Feb 28, 2013 | 4.8 / 5 (10) | 14
Pressure-volume curve: Elastic Recoil Pressure don't make sense
May 18, 2013 From pressure-volume curve of the lung and chest wall (attached photo), I don't understand why would the elastic recoil pressure of the lung is...
If you became brain-dead, would you want them to pull the plug?
May 17, 2013 I'd want the rest of me to stay alive. Sure it's a lousy way to live but it beats being all-the-way dead. Maybe if I make it 20 years they'll...
MRI bill question
May 15, 2013 Dear PFers, The hospital gave us a $12k bill for one MRI (head with contrast). The people I talked to at the hospital tell me that they do not...
Ratio of Hydrogen of Oxygen in Dessicated Animal Protein
May 13, 2013 As an experiment, for the past few months I've been consuming at least one portion of Jell-O or unflavored Knox gelatin per day. I'm 64, in very...
Alcohol and acetaminophen
May 13, 2013 Edit: sorry for the typo in the title , can't edit I looked around on google quite a bit and it's very hard to find precise information on the...
Marie Curie's leukemia
May 13, 2013 Does anyone know what might be the cause of Marie Curie's cancer
- More from Physics Forums - Medical Sciences
More news stories
(Medical Xpress)—Scientists at the School of Medicine have shown that their previously identified therapeutic approach to fight cancer via immune cells called macrophages also prompts the disease-fighting killer T cells ...
Cancer 32 minutes ago | not rated yet | 0 |
Older prostate cancer patients with other underlying health conditions should think twice before committing to surgery or radiation therapy for their cancer, according to a multicenter study led by researchers in the UCLA ...
Cancer 14 hours ago | not rated yet | 0 |
Intensity-modulated radiation therapy has become the most commonly used type of radiation in prostate cancer, but research from the University of North Carolina suggests that the therapy may not be more effective than older, ...
Cancer 15 hours ago | not rated yet | 0
New research suggests that a compound abundant in the Mediterranean diet takes away cancer cells' "superpower" to escape death. By altering a very specific step in gene regulation, this compound essentially re-educates cancer ...
Cancer 16 hours ago | 4.8 / 5 (13) | 3 |
(HealthDay)—For young adults needing either a chest or abdominopelvic computed tomography (CT), the short-term risk of death from underlying morbidity is greater than the long-term risk of radiation-induced ...
Cancer 17 hours ago | not rated yet | 0
(HealthDay)—Injections of a sugar solution appear to help relieve knee pain and stiffness related to osteoarthritis, a new study suggests.
24 minutes ago | not rated yet | 0 |
Over the past few decades, scientists have developed many devices that can reopen clogged arteries, including angioplasty balloons and metallic stents. While generally effective, each of these treatments ...
27 minutes ago | not rated yet | 0 |
(HealthDay)—Obese and overweight men and women who suffer from heartburn often report relief when they lose weight, a new study shows.
14 minutes ago | not rated yet | 0 |
(HealthDay)—When it comes to the care of your children's teeth, dentists aren't the only experts who can help.
34 minutes ago | not rated yet | 0
(HealthDay)—For patients with acute respiratory distress syndrome (ARDS), prolonged prone positioning during mechanical ventilation is associated with significantly reduced mortality at 28 and 90 days, ...
54 minutes ago | not rated yet | 0
(AP)—Tunisia's Health Ministry says a 66-year-old man has died after being infected by the new coronavirus following a visit to Saudi Arabia.
33 minutes ago | not rated yet | 0